Our mission & successes

As a private subsidiary of Inserm, Inserm Transfert manages economic and societal value creation and the transfer of knowledge from Inserm research laboratories to companies contributing to promote human health innovation.

Our mission & successes

As such, it is responsible for Inserm’s second mission: « “contributing […] to value creation of the research results which it conducts or organises ».
(Decree no. 2009-278 of 11 March 2009 modifying decree no. 83-975 of 10 November 1983 on the organisation and operation of the French National Health and Medical Research institute).

Inserm transfert covers Inserm’s three value creation and innovation missions:

  • Protecting and developing innovations from Inserm and its partners :
    • Creating economic and societal value for the benefit of Inserm innovations: detecting, assessing, positioning, protecting, financing proof of concept, orientating, funding, marketing and establishing partnerships ;
    • Developing and co-designing innovations up to the clinical stage ;
    • Being a source of networking and enabling relationships to allow for the emergence of projects;
  • Contributing to Inserm’s reputation and its overall worldwide excellence;
  • Contributing to research funding for Inserm and its partners.

The company also includes specific assistance activities for researchers or clinicians on subjects related to clinical or translational research (cohort studies, public health, databases, etc.).
Inserm Transfert creates synergies by enabling meetings between researchers to understand the type and the potential of their work and, at the same time, by listening to companies in order to identify their strategies and requirements for innovation.
Inserm and Inserm Transfert are a global reference in terms of human health and life sciences innovation and in terms of best practices and technology transfer results. Particular emphasis is placed on medium- and long-term innovations with the very long development cycles that are inherent to biological treatments or to biomarkers, patient stratification methods and diagnostic tests.

Inserm Transfert :

  • Identifies the possible potential of the research as early as possible and sets in place the tools, methods and support in order to create value and protect the initial results;
  • Analyses companies’ requests and contribute to optimal operational formulation by creating a collaborative dynamic between public and private researchers;
  • Runs the research project maturation, from submission of patents to proof of concept, and takes on a proportion of the supportive investment for researchers;
  • Is a pioneer in the future of human health.

The company promotes and facilitates access to the expertise, discoveries and know-how of Inserm’s fundamental research and clinical teams.

*French version

Our mission & successes
Strategic & long term partnerships (Medimmune, AstraZeneca, MSD, 3DS)
Création of growing Startups (HalioDX - Immunoscore®, Enyo Pharma, ImCheck Therapeutics, Eyevensys)
Inserm Transfert is ISO 9001 v2015 certified for all its technology transfer activities
Inserm is the leading academic institute dedicated to biomedical research and human health in Europe
Inserm is at the 2nd place among European patent applicants in the pharmaceutical sector (classifications of the European Patent Office - EPO 2022)
In the biotechnology sector, Inserm is at the 2nd place among European patent applicants (classifications of the European Patent Office - EPO 2022)
1st public / private partnerships on databases and cohorts
Consolidation of SMEs in Medium sized companies
Portfolio of 2321 patents families
High Success rate in collaborative European projects financing (higher than the national end EU average )
Consortium Human Health Startup Factory selected by French Investment Bank (BPI France)